4:08 PM ET
8-K
Business Update
AbbVie Business Update
AbbVie provided a preliminary update for Q3 2026, noting that results will include $216 million in acquired IPR&D and milestones expense, which negatively impacts EPS by $0.11. Consequently, the company updated its full-year 2026 adjusted diluted EPS guidance to a range of $13.76 - $13.96 and its Q3 guidance to $3.73 - $3.77.